Results 81 to 90 of about 65,361 (277)

Are endocannabinoid type 1 receptor gene (CNR1) polymorphisms associated with obesity and metabolic syndrome in postmenopausal Polish women? [PDF]

open access: yes, 2009
Objective: The aim of this study was to determine whether genetic variation at the cannabinoid receptor-1 (CNR1) locus could have an effect on adiposity, fat distribution and obesity-related metabolic disorders in Polish postmenopausal women.Design and ...
Andrzej Milewicz   +5 more
core   +1 more source

Cannabis; epidemiological, neurobiological and psychopathological issues: an update [PDF]

open access: yes, 2017
This document is the Accepted Manuscript version of the following article: Maria Antonietta De Luca, Gaetano Di Chiara, Cristina Cadoni, Daniele Lecca, Laura Orsolini, Duccio Papanti, John Corkery, Fabrizio Schifano, 'Cannabis; Epidemiological ...
Cadoni, Cristina   +7 more
core   +3 more sources

Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain

open access: yesMovement Disorders, EarlyView.
Abstract Background Serotonergic and dopaminergic pathways are implicated in Parkinson's disease psychosis (PDP), but preliminary evidence also implicates the endocannabinoid system (ECS). Objectives We examined the association of gray matter volume loss in PDP patients with brain expression of the genes coding for CB1 (cannabinoid type 1) and CB2 ...
Sara Pisani   +3 more
wiley   +1 more source

Cannabinoids: A New Group of Agonists of PPARs

open access: yesPPAR Research, 2007
Cannabinoids have been used medicinally and recreationally for thousands of years and their effects were proposed to occur mainly via activation of the G-protein-coupled receptor CB1/CB2 (cannabinoid receptor 1/2).
Yan Sun, Andy Bennett
doaj   +1 more source

CB1 Receptor Antagonism Blocks Stress-Potentiated Reinstatement of Cocaine Seeking in Rats [PDF]

open access: yes, 2015
Rationale Under some conditions, stress, rather than directly triggering cocaine seeking, potentiates reinstatement to other stimuli, including a subthreshold cocaine dose.
Baker, David A.   +6 more
core   +2 more sources

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

open access: yesMovement Disorders, EarlyView.
Complement activation is implicated in Huntington's disease; ANX005 is a potent inhibitor of component C1q. ANX005 exhibited a generally manageable safety profile with rapid reduction in C1q in the cerebrospinal fluid. Functional ability on composite Unified Huntington's Disease Rating Scale and total functional capacity was maintained, with potential ...
Rajeev Kumar   +15 more
wiley   +1 more source

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur   +6 more
wiley   +1 more source

Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse [PDF]

open access: yes, 2019
In the isolated rat carotid artery, the endocannabinoid anandamide induces endothelium-dependent relaxation via activation of the enzyme sphingosine kinase (SK).
Alganga, Husam   +10 more
core   +2 more sources

Polypharmacy among adolescents and adults with cerebral palsy in a clinical setting

open access: yesPM&R, EarlyView.
Abstract Background Adolescents and adults with cerebral palsy often experience multimorbidity related to their condition, which primarily affects movement and posture but is also associated with pain, epilepsy, mood disorders, and other conditions. As such, these patients are often prescribed a range of medications to manage symptoms, thereby putting ...
Caitlin Cassidy   +3 more
wiley   +1 more source

Cannabinoid receptor type-1: breaking the dogmas [version 1; referees: 3 approved]

open access: yesF1000Research, 2016
The endocannabinoid system (ECS) is abundantly expressed in the brain. This system regulates a plethora of physiological functions and is composed of cannabinoid receptors, their endogenous ligands (endocannabinoids), and the enzymes involved in the ...
Arnau Busquets Garcia   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy